{"pageContent": "Background: Abiraterone acetate (AA), oral CYP17 inhibitor, is an active agent in the treatment of metastatic castrate-resistant prostate cancer (mCRPC).", "metaData": {"source": "Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion\nhttps://pubmed.ncbi.nlm.nih.gov/12603408/"}}